Trial Profile
A phase I study of ovarian cancer peptides plus GM-CSF and adjuvant (montanide ISA-51) as consolidation following optimal debulking and systemic chemotherapy for women with advanced stage ovarian, tubal, or peritoneal cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Montanide ISA-51 (Primary) ; Ovarian cancer vaccine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Jan 2010 Planned number of patients changed from 9 to 16 as reported by ClinicalTrials.gov.